Stay updated on SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Sign up to get notified when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.

Latest updates to the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoChange DetectedThe record describes a completed Phase 2 study of intranodal immunotherapy combined with pembrolizumab for follicular lymphoma, including its treatment plan, eligibility criteria, and outcome measures. It also provides study contacts, investigators, record dates, and information about sharing participant data.SummaryDifference57%

- Check14 days agoChange DetectedThe site footer now displays revision v3.8.0 instead of v3.7.2; the page still shows a 403 Forbidden error.SummaryDifference0.2%

- Check21 days agoChange DetectedA banner announces that NIH websites are transitioning from the term “artificial intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe footer revision identifier changed from v3.7.1 to v3.7.2.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site footer revision label changes from v3.7.0 to v3.7.1 while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now presents a 403 Forbidden error with a simple header and a Home option. This indicates the study record is inaccessible and the detailed content is no longer displayed.SummaryDifference20%

Stay in the know with updates to SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SIIT + Pembrolizumab in Follicular Lymphoma Clinical Trial page.